123 results
Page 6 of 7
6-K
EX-99.2
wym4lx wrh
7 Nov 18
Quarterly report for entities subject to Listing Rule 4.7B
6:06am
6-K
EX-99.4
tz9bcri
7 Nov 18
Quarterly report for entities subject to Listing Rule 4.7B
6:06am
6-K
EX-99.1
zjr7kh1a
31 Oct 18
Mesoblast Expands Partnership with JCR Pharmaceuticals for Treatment of Wound Healing In Epidermolysis Bullosa
12:00am
6-K
EX-99.1
lyi45d 7dm4
17 Oct 18
Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership In China
6:03am
6-K
EX-99.2
o894x rg5bkaesjek
12 Jul 18
Current report (foreign)
8:25pm
6-K
EX-99.3
0xh0p7z0a 09g
5 Jul 18
Current report (foreign)
12:00am
6-K
EX-99.1
r1prn
28 Jun 18
Current report (foreign)
12:00am
6-K
EX-99.1
uti85zrxaf7
20 Jun 18
U.s. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board
12:00am
6-K
EX-99.2
ejvl0a
1 Jun 18
Current report (foreign)
12:00am
6-K
0wjqkb8c3ehp116i
1 Jun 18
Current report (foreign)
12:00am
6-K
EX-99.2
aomtq
4 May 18
Quarterly report for entities subject to Listing Rule 4.7B
7:50am
6-K
EX-99.1
zm9jpfwkruojxzvu176
20 Apr 18
Mesoblast Clinical Program Update for MPC-150-IM In Patients with Chronic Heart Failure
12:00am
6-K
EX-99.2
gga8ecgon7t kma
18 Oct 17
Current report (foreign)
12:00am
6-K
EX-99.1
kor2m2
18 Oct 17
Current report (foreign)
12:00am
6-K
EX-99.1
gmcwj23 7k1rxjphoi0
26 Oct 16
Current report (foreign)
12:00am
20-F
zduvm
25 Aug 16
Annual report (foreign)
12:00am
DRS/A
8khinxatcbwrf7qervel
7 Oct 15
Draft registration statement (amended)
12:00am
DRS/A
8a87v6m 1f
9 Jan 15
Draft registration statement (amended)
12:00am